PR Newswire Clinical TrialsOriginal article
Dasher Neuroscience schließt die Patientenrekrutierung für die weltweite klinische Phase-2-Studie mit dem führenden KI-basierten Wirkstoffkandidaten YA-101 gegen Multisystematrophie (MSA) ab
Phase 2YA-101Positive
AI Analysis
Summary
Dasher Neuroscience completed patient recruitment for its global Phase 2 trial of YA-101, an AI-based therapeutic candidate for multisystemic atrophy. The trial advancement represents progress in the development of this CNS-focused candidate.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Patient recruitment completed for global Phase 2 clinical trial
Importance:6/10
Sentiment:
0.60
clinical-trialphase-2AI-drivenCNSrare-diseasepatient-recruitment
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 30, 2026 5:29 AM